Vimarsana
Biggest News Aggregation in the World

Versus Lenalidomide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Versus Lenalidomide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Versus Lenalidomide Today - Breaking & Trending Today

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting - Vimarsana News

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting

SEATTLE, Dec. 05, 2023 -- Adaptive Biotechnologies Corporation , a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to...

National Institute for Health and Care Excellence gives green light to Darzalex® (daratumumab) with lenalidomide and dexamethasone for patients with n - Vimarsana News

National Institute for Health and Care Excellence gives green light to Darzalex® (daratumumab) with lenalidomide and dexamethasone for patients with n

Daratumumab combination is recommended for use within the NHS in England and Wales for treating adults with newly diagnosed multiple myeloma where a stem cell transplant is unsuitableEligible patients throughout England and Wales can now access alternative combination treatment option which has been shown to delay d...

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma - Vimarsana News

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab)...

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting - Vimarsana News

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Clinical Utility and Benefit of clonoSEQ MRD Testing in Blood Cancer Patients at 2022 ASH Annual Meeting

05.12.2022 - SEATTLE, Dec. 05, 2022 (GLOBE NEWSWIRE) - Adaptive Biotechnologies Corporation (Nasdaq: ADPT), together with its collaborators, will present data from more than 30 abstracts showcasing the benefit of Adaptive’s next-generation sequencing ...

New Clinical and Real-World Data Support Use of DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma - Vimarsana News

New Clinical and Real-World Data Support Use of DARZALEX®▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma

Investigational daratumumab quadruple combination regimen shows responses in newly diagnosed, transplant-eligible patients with multiple myeloma in randomised Phase 2 GRIFFIN study1 Real-world...